Learn how causal mechanism and effect analysis (CMEA) and its principles can be used to develop and maintain safer working environments in the pharma/biotech and medical device industries.
- In Bioprocessing, Trusted Data Is A Process Variable
- Are Biopharma Companies Outsourcing Their Ability To Think?
- Why Operational Readiness Is The Missing Piece In Biosimilar Adoption
- Demonstrating Non-Inferiority Of BFPCs Vs. Traditional Air Monitoring
- Exploring Takeda's Template For Sustainable Steam Generation
- Transforming Computer System Validation In The Life Sciences Industry
- Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis
GUEST COLUMNISTS
-
In Bioprocessing, Trusted Data Is A Process Variable
As digital systems become increasingly interconnected, digital validation ensures systems generating and managing GxP data remain accurate, consistent, and trustworthy.
-
Are Biopharma Companies Outsourcing Their Ability To Think?
Amid gaining immediate access to external manufacturing capabilities, sponsor companies can lose the foundational understanding required to govern that capability.
-
Why Operational Readiness Is The Missing Piece In Biosimilar Adoption
Biosimilar success depends on seamless execution. Strong care coordination, patient education, and operational readiness are essential to improve access, adherence, and outcomes.
-
Demonstrating Non-Inferiority Of BFPCs Vs. Traditional Air Monitoring
Demonstrating non-inferiority of bio-fluorescent particle counter (BFPC) technology to traditional active air-sampling methods is essential for implementation. Here's how to approach it.
-
Exploring Takeda's Template For Sustainable Steam Generation
Takeda designed a model for delivering steam at 11 bar and up to 184 degrees using natural refrigerant and waste heat at one of its largest production sites.
-
Transforming Computer System Validation In The Life Sciences Industry
Regulators acknowledge how traditional CSV methods fail to meet modern demands for speed and flexibility. The scene is changing in favor of smarter, leaner validation.
-
Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis
Since every sponsor–CDMO relationship can have widely different scopes, requirements, and procedures, this article focuses on the basic principles for analyzing and managing the risks of not achieving the relationship’s objectives.
BIOSIMILAR WHITE PAPERS
-
Process Analytical Technology In The ADC Bioconjugation Process
Integrating Process Analytical Technology into validated GMP processes is complex and costly, which requires thorough validation of equipment and cleaning methods. Explore more about PAT's role in ADC production.
-
Biopharma Supply, Reimagined: Regional, Resilient Manufacturing4/1/2026
Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
-
A Risk-Based Approach To Plasmid DNA And mRNA Process Development9/23/2025
Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
-
Perfusion Cell Line Development For Intensified Processes5/5/2025
The biopharmaceutical industry is transforming by shifting to continuous and intensified upstream bioprocesses, which are driven by evolving demands. Discover the key goals and innovations shaping this transition for modern healthcare.
-
A Comprehensive Solution For Adventitious Agent Testing2/13/2026
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
-
A Supplier-Manufacturer Approach To Mitigating Nitrosamine Risk10/10/2024
Learn about how nitrosamines are formed, their prevalence and chemical precursors in pharmaceuticals, techniques for quantification, and approaches for managing nitrite impurities.
BIOSIMILAR APP NOTES & CASE STUDIES
- Scalable rAAV9 Production Using Advanced Cell Lines And Bioreactors
- Automation And Digital Solutions Can Help You Reach Your mRNA Manufacturing And Sustainability Goals
- Evaluating Antibody Fragment Purification Using VH3 Resin
- Microbial Integrity Of Sampling Systems After Multiple Actuations
- Seed Train Intensification Using High Cell Density Cryopreservation
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- AEON Reports Expanded Structural Data Supporting Molecular Similarity Of ABP-450 To BOTOX®
- Avalon Pharma And Bio-Thera Execute Exclusive Commercialization Agreement For BAT2406, A Proposed Dupixent Biosimilar, For MENA
- Henlius And Sandoz Enter Strategic Collaboration To Unlock Global Value Of Biosimilars Platform
- New Study From CVS Caremark And Employee Benefit News Shows How Employers Rely On Their Pharmacy Benefit Manager To Create Sustainable Pharmacy Solutions
- Mabwell Announces Strategic Partnerships For Aflibercept Biosimilar In Multiple ASEAN Countries
- Henlius Accelerates The New Landscape Of Breast Cancer Treatment As HANQUYOU Marks Six Years Since Its Approval
- Samsung Bioepis Launches OPUVIZ (Aflibercept) 40 mg/mL Pre-Filled Syringe Across Europe
- Amneal Completes Acquisition Of Kashiv BioSciences, Creating A Global Biosimilar Leader
NEWSLETTER ARCHIVE
- 08.20.26 -- Exploring Takeda's Template For Sustainable Steam Generation
- 08.13.26 -- When Innovation Meets Scale
- 08.13.26 -- Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis
- 08.06.26 -- Achieving Annex 1 Compliance In Sterile Manufacturing
- 07.30.26 -- FDA Explains How To Respond To Form 483 Observations